Gastric Cancer Market By Disease Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others), By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery), By Drug Class Outlook (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Specialty and Retail Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global gastric cancer market is anticipated to reach $10.7 billion by 2031, growing from $2.1 billion in 2021, at a CAGR of 17.9% from 2022 to 2031.
Gastric cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. Age, diet, and sedentary lifestyle can lead to the risk of developing gastric cancer. Symptoms of gastric cancer include indigestion and stomach discomfort or pain. Tests that examine the stomach and esophagus are used to diagnose gastric cancer.
The gastric cancer market is expected to expand as cases of the stomach disease rise. The causes of stomach cancer have significantly increased due to additional risk factors such as an increase in obesity, increase in the consumption of highly processed foods, sugary beverages, smoking, genetic modification of genes, a family history of cancer, and consumption of alcohol. Furthermore, the rising incidence of gastric cancer is anticipated to continue and this trend is boosting the demand for efficient treatments. All these factors are projected to drive the market revenue growth during the forecast period.
Gastric cancer treatment can be expensive as there are numerous tests which need to be conducted, including surgery, radiation therapy, and diagnosis, and staging. Different tests and procedures, such as imaging studies, endoscopies, biopsies, and blood tests, are frequently required in the diagnosis and staging of gastric cancer. The cost of these tests can be high, and multiple doctor visits might be necessary. The market is predicted to be severely constrained by the high cost of treating gastric cancer.
The market for gastric cancer is projected to benefit due to the increase in healthcare awareness. People are more likely to seek medical attention and get screened for the disease as they become more aware of the risk factors linked to gastric cancer. More cases of gastric cancer can be discovered at an earlier stage owing to the increase in awareness. Early detection of gastric cancer is essential for effective treatment and better patient outcomes. Therefore, gastric cancer patient may need diagnostic and therapeutic options like medication, surgery, and radiation therapy. These factors are expected to create several growth opportunities for the major players operating in the market.
The COVID-19 pandemic had a detrimental effect on the treatment of gastric cancer, especially in terms of the timing of screening, diagnosis, and treatment.COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the post-pandemic period. Many gastric cancer patients have experienced treatment interruptions due to the pandemic. To reduce the risk of COVID-19 transmission, treatment schedules had to be altered, which resulted in delays or changes to some patients' treatment plans. Concerns about COVID-19 exposure in healthcare settings made patients hesitant to seek treatment. Clinical trials for gastric cancer were significantly impacted by the pandemic as numerous clinical trials were postponed or delayed.
The key players profiled in this report include Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis and Bristol Myers Squibb Company
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastric cancer market analysis from 2021 to 2031 to identify the prevailing gastric cancer market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the gastric cancer market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global gastric cancer market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Type
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others
By Treatment Type
Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy and Surgery
By Drug Class Outlook
PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Specialty and Retail Pharmacies
Others
Hospital Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
United Arab Emirates
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Novartis AG
Pfizer, Inc.
Mylan N.V.
F. Hoffmann La Roche Ltd.
Eli Lilly And Company
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Celltrion Healthcare Co., Ltd.
samsung bioepis
Bristol Myers Squibb Company
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- 3.5. COVID-19 Impact Analysis on the market
- 3.6. Average Selling Price
- 3.7. Brand Share Analysis
- 3.8. Key Regulation Analysis
- 3.9. Market Share Analysis
- 3.10. Patent Landscape
- 3.11. Regulatory Guidelines
- 3.12. Value Chain Analysis
- CHAPTER 4: GASTRIC CANCER MARKET, BY DISEASE TYPE
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Adenocarcinoma
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Lymphoma
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Gastrointestinal Stromal Tumor
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Carcinoid Tumor
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- 4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
- CHAPTER 5: GASTRIC CANCER MARKET, BY TREATMENT TYPE
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Immunotherapy
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Targeted Therapy
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Chemotherapy
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- 5.5. Radiation Therapy and Surgery
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
- CHAPTER 6: GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. PD-1/PD-L1 Inhibitors
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. HER2 Antagonists
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. VEGFR2 Antagonists
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- 6.5. Others
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country
- CHAPTER 7: GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION
- 7.1. Overview
- 7.1.1. Market size and forecast
- 7.2. Oral
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
- 7.3. Injectable
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
- CHAPTER 8: GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL
- 8.1. Overview
- 8.1.1. Market size and forecast
- 8.2. Hospital Pharmacies
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by region
- 8.2.3. Market share analysis by country
- 8.3. Specialty and Retail Pharmacies
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by region
- 8.3.3. Market share analysis by country
- 8.4. Others
- 8.4.1. Key market trends, growth factors and opportunities
- 8.4.2. Market size and forecast, by region
- 8.4.3. Market share analysis by country
- CHAPTER 9: GASTRIC CANCER MARKET, BY REGION
- 9.1. Overview
- 9.1.1. Market size and forecast By Region
- 9.2. North America
- 9.2.1. Key trends and opportunities
- 9.2.2. Market size and forecast, by Disease Type
- 9.2.3. Market size and forecast, by Treatment Type
- 9.2.4. Market size and forecast, by Drug Class Outlook
- 9.2.5. Market size and forecast, by Route of Administration
- 9.2.6. Market size and forecast, by Distribution Channel
- 9.2.7. Market size and forecast, by country
- 9.2.7.1. U.S.
- 9.2.7.1.1. Key market trends, growth factors and opportunities
- 9.2.7.1.2. Market size and forecast, by Disease Type
- 9.2.7.1.3. Market size and forecast, by Treatment Type
- 9.2.7.1.4. Market size and forecast, by Drug Class Outlook
- 9.2.7.1.5. Market size and forecast, by Route of Administration
- 9.2.7.1.6. Market size and forecast, by Distribution Channel
- 9.2.7.2. Canada
- 9.2.7.2.1. Key market trends, growth factors and opportunities
- 9.2.7.2.2. Market size and forecast, by Disease Type
- 9.2.7.2.3. Market size and forecast, by Treatment Type
- 9.2.7.2.4. Market size and forecast, by Drug Class Outlook
- 9.2.7.2.5. Market size and forecast, by Route of Administration
- 9.2.7.2.6. Market size and forecast, by Distribution Channel
- 9.2.7.3. Mexico
- 9.2.7.3.1. Key market trends, growth factors and opportunities
- 9.2.7.3.2. Market size and forecast, by Disease Type
- 9.2.7.3.3. Market size and forecast, by Treatment Type
- 9.2.7.3.4. Market size and forecast, by Drug Class Outlook
- 9.2.7.3.5. Market size and forecast, by Route of Administration
- 9.2.7.3.6. Market size and forecast, by Distribution Channel
- 9.3. Europe
- 9.3.1. Key trends and opportunities
- 9.3.2. Market size and forecast, by Disease Type
- 9.3.3. Market size and forecast, by Treatment Type
- 9.3.4. Market size and forecast, by Drug Class Outlook
- 9.3.5. Market size and forecast, by Route of Administration
- 9.3.6. Market size and forecast, by Distribution Channel
- 9.3.7. Market size and forecast, by country
- 9.3.7.1. Germany
- 9.3.7.1.1. Key market trends, growth factors and opportunities
- 9.3.7.1.2. Market size and forecast, by Disease Type
- 9.3.7.1.3. Market size and forecast, by Treatment Type
- 9.3.7.1.4. Market size and forecast, by Drug Class Outlook
- 9.3.7.1.5. Market size and forecast, by Route of Administration
- 9.3.7.1.6. Market size and forecast, by Distribution Channel
- 9.3.7.2. UK
- 9.3.7.2.1. Key market trends, growth factors and opportunities
- 9.3.7.2.2. Market size and forecast, by Disease Type
- 9.3.7.2.3. Market size and forecast, by Treatment Type
- 9.3.7.2.4. Market size and forecast, by Drug Class Outlook
- 9.3.7.2.5. Market size and forecast, by Route of Administration
- 9.3.7.2.6. Market size and forecast, by Distribution Channel
- 9.3.7.3. France
- 9.3.7.3.1. Key market trends, growth factors and opportunities
- 9.3.7.3.2. Market size and forecast, by Disease Type
- 9.3.7.3.3. Market size and forecast, by Treatment Type
- 9.3.7.3.4. Market size and forecast, by Drug Class Outlook
- 9.3.7.3.5. Market size and forecast, by Route of Administration
- 9.3.7.3.6. Market size and forecast, by Distribution Channel
- 9.3.7.4. Spain
- 9.3.7.4.1. Key market trends, growth factors and opportunities
- 9.3.7.4.2. Market size and forecast, by Disease Type
- 9.3.7.4.3. Market size and forecast, by Treatment Type
- 9.3.7.4.4. Market size and forecast, by Drug Class Outlook
- 9.3.7.4.5. Market size and forecast, by Route of Administration
- 9.3.7.4.6. Market size and forecast, by Distribution Channel
- 9.3.7.5. Italy
- 9.3.7.5.1. Key market trends, growth factors and opportunities
- 9.3.7.5.2. Market size and forecast, by Disease Type
- 9.3.7.5.3. Market size and forecast, by Treatment Type
- 9.3.7.5.4. Market size and forecast, by Drug Class Outlook
- 9.3.7.5.5. Market size and forecast, by Route of Administration
- 9.3.7.5.6. Market size and forecast, by Distribution Channel
- 9.3.7.6. Rest of Europe
- 9.3.7.6.1. Key market trends, growth factors and opportunities
- 9.3.7.6.2. Market size and forecast, by Disease Type
- 9.3.7.6.3. Market size and forecast, by Treatment Type
- 9.3.7.6.4. Market size and forecast, by Drug Class Outlook
- 9.3.7.6.5. Market size and forecast, by Route of Administration
- 9.3.7.6.6. Market size and forecast, by Distribution Channel
- 9.4. Asia-Pacific
- 9.4.1. Key trends and opportunities
- 9.4.2. Market size and forecast, by Disease Type
- 9.4.3. Market size and forecast, by Treatment Type
- 9.4.4. Market size and forecast, by Drug Class Outlook
- 9.4.5. Market size and forecast, by Route of Administration
- 9.4.6. Market size and forecast, by Distribution Channel
- 9.4.7. Market size and forecast, by country
- 9.4.7.1. China
- 9.4.7.1.1. Key market trends, growth factors and opportunities
- 9.4.7.1.2. Market size and forecast, by Disease Type
- 9.4.7.1.3. Market size and forecast, by Treatment Type
- 9.4.7.1.4. Market size and forecast, by Drug Class Outlook
- 9.4.7.1.5. Market size and forecast, by Route of Administration
- 9.4.7.1.6. Market size and forecast, by Distribution Channel
- 9.4.7.2. Japan
- 9.4.7.2.1. Key market trends, growth factors and opportunities
- 9.4.7.2.2. Market size and forecast, by Disease Type
- 9.4.7.2.3. Market size and forecast, by Treatment Type
- 9.4.7.2.4. Market size and forecast, by Drug Class Outlook
- 9.4.7.2.5. Market size and forecast, by Route of Administration
- 9.4.7.2.6. Market size and forecast, by Distribution Channel
- 9.4.7.3. India
- 9.4.7.3.1. Key market trends, growth factors and opportunities
- 9.4.7.3.2. Market size and forecast, by Disease Type
- 9.4.7.3.3. Market size and forecast, by Treatment Type
- 9.4.7.3.4. Market size and forecast, by Drug Class Outlook
- 9.4.7.3.5. Market size and forecast, by Route of Administration
- 9.4.7.3.6. Market size and forecast, by Distribution Channel
- 9.4.7.4. South Korea
- 9.4.7.4.1. Key market trends, growth factors and opportunities
- 9.4.7.4.2. Market size and forecast, by Disease Type
- 9.4.7.4.3. Market size and forecast, by Treatment Type
- 9.4.7.4.4. Market size and forecast, by Drug Class Outlook
- 9.4.7.4.5. Market size and forecast, by Route of Administration
- 9.4.7.4.6. Market size and forecast, by Distribution Channel
- 9.4.7.5. Australia
- 9.4.7.5.1. Key market trends, growth factors and opportunities
- 9.4.7.5.2. Market size and forecast, by Disease Type
- 9.4.7.5.3. Market size and forecast, by Treatment Type
- 9.4.7.5.4. Market size and forecast, by Drug Class Outlook
- 9.4.7.5.5. Market size and forecast, by Route of Administration
- 9.4.7.5.6. Market size and forecast, by Distribution Channel
- 9.4.7.6. Rest of Asia-Pacific
- 9.4.7.6.1. Key market trends, growth factors and opportunities
- 9.4.7.6.2. Market size and forecast, by Disease Type
- 9.4.7.6.3. Market size and forecast, by Treatment Type
- 9.4.7.6.4. Market size and forecast, by Drug Class Outlook
- 9.4.7.6.5. Market size and forecast, by Route of Administration
- 9.4.7.6.6. Market size and forecast, by Distribution Channel
- 9.5. LAMEA
- 9.5.1. Key trends and opportunities
- 9.5.2. Market size and forecast, by Disease Type
- 9.5.3. Market size and forecast, by Treatment Type
- 9.5.4. Market size and forecast, by Drug Class Outlook
- 9.5.5. Market size and forecast, by Route of Administration
- 9.5.6. Market size and forecast, by Distribution Channel
- 9.5.7. Market size and forecast, by country
- 9.5.7.1. Brazil
- 9.5.7.1.1. Key market trends, growth factors and opportunities
- 9.5.7.1.2. Market size and forecast, by Disease Type
- 9.5.7.1.3. Market size and forecast, by Treatment Type
- 9.5.7.1.4. Market size and forecast, by Drug Class Outlook
- 9.5.7.1.5. Market size and forecast, by Route of Administration
- 9.5.7.1.6. Market size and forecast, by Distribution Channel
- 9.5.7.2. United Arab Emirates
- 9.5.7.2.1. Key market trends, growth factors and opportunities
- 9.5.7.2.2. Market size and forecast, by Disease Type
- 9.5.7.2.3. Market size and forecast, by Treatment Type
- 9.5.7.2.4. Market size and forecast, by Drug Class Outlook
- 9.5.7.2.5. Market size and forecast, by Route of Administration
- 9.5.7.2.6. Market size and forecast, by Distribution Channel
- 9.5.7.3. Saudi Arabia
- 9.5.7.3.1. Key market trends, growth factors and opportunities
- 9.5.7.3.2. Market size and forecast, by Disease Type
- 9.5.7.3.3. Market size and forecast, by Treatment Type
- 9.5.7.3.4. Market size and forecast, by Drug Class Outlook
- 9.5.7.3.5. Market size and forecast, by Route of Administration
- 9.5.7.3.6. Market size and forecast, by Distribution Channel
- 9.5.7.4. South Africa
- 9.5.7.4.1. Key market trends, growth factors and opportunities
- 9.5.7.4.2. Market size and forecast, by Disease Type
- 9.5.7.4.3. Market size and forecast, by Treatment Type
- 9.5.7.4.4. Market size and forecast, by Drug Class Outlook
- 9.5.7.4.5. Market size and forecast, by Route of Administration
- 9.5.7.4.6. Market size and forecast, by Distribution Channel
- 9.5.7.5. Rest of LAMEA
- 9.5.7.5.1. Key market trends, growth factors and opportunities
- 9.5.7.5.2. Market size and forecast, by Disease Type
- 9.5.7.5.3. Market size and forecast, by Treatment Type
- 9.5.7.5.4. Market size and forecast, by Drug Class Outlook
- 9.5.7.5.5. Market size and forecast, by Route of Administration
- 9.5.7.5.6. Market size and forecast, by Distribution Channel
- CHAPTER 10: COMPETITIVE LANDSCAPE
- 10.1. Introduction
- 10.2. Top winning strategies
- 10.3. Product Mapping of Top 10 Player
- 10.4. Competitive Dashboard
- 10.5. Competitive Heatmap
- 10.6. Top player positioning, 2021
- CHAPTER 11: COMPANY PROFILES
- 11.1. Novartis AG
- 11.1.1. Company overview
- 11.1.2. Key Executives
- 11.1.3. Company snapshot
- 11.2. Pfizer, Inc.
- 11.2.1. Company overview
- 11.2.2. Key Executives
- 11.2.3. Company snapshot
- 11.3. Mylan N.V.
- 11.3.1. Company overview
- 11.3.2. Key Executives
- 11.3.3. Company snapshot
- 11.4. F. Hoffmann La Roche Ltd.
- 11.4.1. Company overview
- 11.4.2. Key Executives
- 11.4.3. Company snapshot
- 11.5. Eli Lilly And Company
- 11.5.1. Company overview
- 11.5.2. Key Executives
- 11.5.3. Company snapshot
- 11.6. Merck & Co., Inc.
- 11.6.1. Company overview
- 11.6.2. Key Executives
- 11.6.3. Company snapshot
- 11.7. Teva Pharmaceutical Industries Ltd.
- 11.7.1. Company overview
- 11.7.2. Key Executives
- 11.7.3. Company snapshot
- 11.8. Celltrion Healthcare Co., Ltd.
- 11.8.1. Company overview
- 11.8.2. Key Executives
- 11.8.3. Company snapshot
- 11.9. samsung bioepis
- 11.9.1. Company overview
- 11.9.2. Key Executives
- 11.9.3. Company snapshot
- 11.10. Bristol Myers Squibb Company
- 11.10.1. Company overview
- 11.10.2. Key Executives
- 11.10.3. Company snapshot
- LIST OF TABLES
- TABLE 01. GLOBAL GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 02. GASTRIC CANCER MARKET FOR ADENOCARCINOMA, BY REGION, 2021-2031 ($MILLION)
- TABLE 03. GASTRIC CANCER MARKET FOR LYMPHOMA, BY REGION, 2021-2031 ($MILLION)
- TABLE 04. GASTRIC CANCER MARKET FOR GASTROINTESTINAL STROMAL TUMOR, BY REGION, 2021-2031 ($MILLION)
- TABLE 05. GASTRIC CANCER MARKET FOR CARCINOID TUMOR, BY REGION, 2021-2031 ($MILLION)
- TABLE 06. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 07. GLOBAL GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 08. GASTRIC CANCER MARKET FOR IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)
- TABLE 09. GASTRIC CANCER MARKET FOR TARGETED THERAPY, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. GASTRIC CANCER MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. GASTRIC CANCER MARKET FOR RADIATION THERAPY AND SURGERY, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. GLOBAL GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 13. GASTRIC CANCER MARKET FOR PD-1/PD-L1 INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. GASTRIC CANCER MARKET FOR HER2 ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 15. GASTRIC CANCER MARKET FOR VEGFR2 ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 17. GLOBAL GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 18. GASTRIC CANCER MARKET FOR ORAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 19. GASTRIC CANCER MARKET FOR INJECTABLE, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. GLOBAL GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 21. GASTRIC CANCER MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 22. GASTRIC CANCER MARKET FOR SPECIALTY AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 23. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 24. GASTRIC CANCER MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 25. NORTH AMERICA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 26. NORTH AMERICA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 27. NORTH AMERICA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 28. NORTH AMERICA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 29. NORTH AMERICA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 31. U.S. GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 32. U.S. GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 33. U.S. GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 34. U.S. GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 35. U.S. GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 36. CANADA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 37. CANADA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 38. CANADA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 39. CANADA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 40. CANADA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 41. MEXICO GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 42. MEXICO GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 43. MEXICO GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 44. MEXICO GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 45. MEXICO GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 46. EUROPE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 47. EUROPE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 48. EUROPE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 49. EUROPE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 50. EUROPE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 51. EUROPE GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 52. GERMANY GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 53. GERMANY GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 54. GERMANY GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 55. GERMANY GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 56. GERMANY GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 57. UK GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 58. UK GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 59. UK GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 60. UK GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 61. UK GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 62. FRANCE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 63. FRANCE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 64. FRANCE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 65. FRANCE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 66. FRANCE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 67. SPAIN GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 68. SPAIN GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 69. SPAIN GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 70. SPAIN GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 71. SPAIN GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 72. ITALY GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 73. ITALY GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 74. ITALY GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 75. ITALY GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 76. ITALY GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 77. REST OF EUROPE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 78. REST OF EUROPE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 79. REST OF EUROPE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 80. REST OF EUROPE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 81. REST OF EUROPE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 82. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 83. ASIA-PACIFIC GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 84. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 85. ASIA-PACIFIC GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 86. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 87. ASIA-PACIFIC GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 88. CHINA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 89. CHINA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 90. CHINA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 91. CHINA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 92. CHINA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 93. JAPAN GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 94. JAPAN GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 95. JAPAN GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 96. JAPAN GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 97. JAPAN GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 98. INDIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 99. INDIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 100. INDIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 101. INDIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 102. INDIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 103. SOUTH KOREA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 104. SOUTH KOREA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 105. SOUTH KOREA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 106. SOUTH KOREA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 107. SOUTH KOREA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 108. AUSTRALIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 109. AUSTRALIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 110. AUSTRALIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 111. AUSTRALIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 112. AUSTRALIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 113. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 114. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 115. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 116. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 117. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 118. LAMEA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 119. LAMEA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 120. LAMEA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 121. LAMEA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 122. LAMEA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 123. LAMEA GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 124. BRAZIL GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 125. BRAZIL GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 126. BRAZIL GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 127. BRAZIL GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 128. BRAZIL GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 129. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 130. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 131. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 132. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 133. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 134. SAUDI ARABIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 135. SAUDI ARABIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 136. SAUDI ARABIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 137. SAUDI ARABIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 138. SAUDI ARABIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 139. SOUTH AFRICA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 140. SOUTH AFRICA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 141. SOUTH AFRICA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 142. SOUTH AFRICA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 143. SOUTH AFRICA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 144. REST OF LAMEA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 145. REST OF LAMEA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
- TABLE 146. REST OF LAMEA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
- TABLE 147. REST OF LAMEA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 148. REST OF LAMEA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 149. NOVARTIS AG: KEY EXECUTIVES
- TABLE 150. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 151. PFIZER, INC.: KEY EXECUTIVES
- TABLE 152. PFIZER, INC.: COMPANY SNAPSHOT
- TABLE 153. MYLAN N.V.: KEY EXECUTIVES
- TABLE 154. MYLAN N.V.: COMPANY SNAPSHOT
- TABLE 155. F. HOFFMANN LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 156. F. HOFFMANN LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 157. ELI LILLY AND COMPANY: KEY EXECUTIVES
- TABLE 158. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
- TABLE 159. MERCK & CO., INC.: KEY EXECUTIVES
- TABLE 160. MERCK & CO., INC.: COMPANY SNAPSHOT
- TABLE 161. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 162. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 163. CELLTRION HEALTHCARE CO., LTD.: KEY EXECUTIVES
- TABLE 164. CELLTRION HEALTHCARE CO., LTD.: COMPANY SNAPSHOT
- TABLE 165. SAMSUNG BIOEPIS: KEY EXECUTIVES
- TABLE 166. SAMSUNG BIOEPIS: COMPANY SNAPSHOT
- TABLE 167. BRISTOL MYERS SQUIBB COMPANY: KEY EXECUTIVES
- TABLE 168. BRISTOL MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
- LIST OF FIGURES
- FIGURE 01. GASTRIC CANCER MARKET, 2021-2031
- FIGURE 02. SEGMENTATION OF GASTRIC CANCER MARKET, 2021-2031
- FIGURE 03. TOP INVESTMENT POCKETS IN GASTRIC CANCER MARKET (2022-2031)
- FIGURE 04. PORTER FIVE-1
- FIGURE 05. PORTER FIVE-2
- FIGURE 06. PORTER FIVE-3
- FIGURE 07. PORTER FIVE-4
- FIGURE 08. PORTER FIVE-5
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPO
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook